Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52. The key difference: iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SGOV | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Fixed Income |
52-Week High | $491.22 | $100.74 |
52-Week Low | $278.09 | $100.28 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.50, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bearish trend from moving averages, though oscillators are neutral. The ETF functions as a cash management vehicle, holding ultra-short-term U.S. Treasury bills, with key financial ratios like P/E and P/B not applicable due to its structure. Recent news highlights strong investor inflows into short-term bond ETFs amid rate uncertainty.
The outlook for SGOV remains stable, offering a low-risk haven for cash with yields around 3.5–3.6%, appealing in volatile markets. Risks include potential Fed rate hikes reducing relative yield appeal and inflation eroding returns. Analyst sentiment is positive for its role in agile, income-focused portfolios, but investors should weigh opportunity costs against equity investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
